Elbasvir Not Yet Recruiting Phase 3 Trials for Metabolic Syndromes / Chronic hepatitis C genotype 1b / Cirrhoses, Liver / Fibrosis, Liver Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03222167Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b